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Abstract 
Gemcitabine, 2’-deoxy-2’,2’-difluorocytidine, is currently prescribed against a number 
of cancers. Here we report a linear synthesis of gemcitabine with a high-yielding 
direct conversion of 3,5-di-O-benzoyl-2-deoxy-2,2-difluororibose into the 
corresponding glycosyl urea as the key step, followed by conventional conversion to 
the cytosine base via the uracil derivative. The process proceeded with modest 
anomeric selectivity. 
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Gemcitabine 1 (Scheme 1), marketed by its discoverer Lilly as the HCl salt under the 
trade name of Gemzar, is a widely prescribed anticancer drug against pancreatic, 
ovarian and breast cancer. Before its recent patent expiry, it was a $1 bn dollar per 
annum drug, and while sales have now dropped below that figure, its market 
continues to grow. It is a fluorinated nucleoside1-6 prodrug, undergoing intracellular 
phosphorylation to its active diphosphate and triphosphate form, which inhibits DNA 
synthesis leading to apoptosis.7-11  
 
 
Scheme 1: Convergent nucleobase introduction in the synthesis of gemcitabine 1. 
The synthesis of gemcitabine12 has been subject to tremendous and –spurred by the 
Lilly patent expiry– still continuing efforts.13 In general, a convergent synthesis has 
been applied, in which a suitably protected and activated 2-deoxy-2,2-
difluororibofuranose derivative 2 (Scheme 1) is combined with an activated cytosine 
base, eg 3. Much optimisation has been devoted to an efficient 2-deoxy-2,2-
difluororibofuranose synthesis, a feat which has now largely been achieved through 
use of specific alcohol protecting groups allowing efficient and high-yielding 
diastereomer separation by crystallisation(s). The nucleobase introduction reaction 
has also been subject to intensive research. This process is made difficult by the 
difluorination at the sugar 2-position, and typically leads to an anomeric mixture. 
Again, selective crystallisation procedures have been developed to obtain 
anomerically pure gemcitabine.13  
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While alternative linear nucleoside syntheses are common in the carbanucleoside 
field,14-16 this strategy has to our knowledge been applied only once for the 
gemcitabine synthesis (Scheme 2a).17  
 
 
Scheme 2. Linear gemcitabine synthesis.  
 
Here the sugar donor 5 was reacted with the N-2-cyanovinyl amide 4 to give the 
intermediate 6, after which the cytosine synthesis was completed by base-induced 
cyclisation. An overall yield of 12% was reported. A linear synthesis is also possible – 
but not reported – from the corresponding amino-2-deoxy-2,2-difluoroglycoside 9, 
which has been synthesised in two steps by a Lilly group.18 (Scheme 2b). However, 
while 9 was obtained in high yield, no anomeric selectivity was obtained, and the 
anomeric ratio of 9 was independent of the anomeric ratio of the azide precursor 8, 
suggesting an equilibration process. 
Herein we describe our efforts leading to an alternative linear gemcitabine synthesis. 
In order to avoid the abovementioned anomerisation at the aminoglycoside stage, a 
nucleobase construction strategy starting from the corresponding glycosyl urea 10 
was envisioned (Scheme 3). It was hoped that the possible crystallinity of this urea 
derivative would offer anomeric purification prospects. 
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Scheme 3. 
 
In addition, it was planned to introduce the urea by a direct condensation reaction 
with the known 3,5-di-O-benzoyl-2-deoxy-2,2-difluororibose 11, thus bypassing the 
need for anomeric activation. This protected difluororibose derivative was first 
described by a Lilly group,19 but obtained by us by reduction of the commercially 
available dibenzoylated difluororibonolactone.  
 
2. Results and discussion 
2.1 Urea condensation 
The work commenced by investigating the direct urea introduction. The acid-
catalysed condensation of aldehydes with urea has been reported in high yields,20,21 
and there were few reports available of this process with unprotected (and 
unfluorinated) carbohydrates.22,23 In recent years, the reaction of unprotected and 
non-activated carbohydrates with ureas has received renewed attention, and has 
typically been achieved with an acid-catalyst.24 Hence, it was first investigated 
whether the acid-catalysed condensation of a difluorinated sugar such as furanose 
11 was possible with ureas. Initially, the 5-O-TBDPS lactol 12 was used as substrate 
(Table 1), and to avoid complication by the urea reacting at both ends, N,N-dimethyl 
urea 12 was used.  
 
Table 1. Optimisation of the urea condensation reaction. 
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[a]
 Isolated yield. [b] Remove reaction solvent by evaporation in vacuo. [c] Filtration over silica. [d] Filtration 
over celite. [e] 2.3 mmol scale. 
 
Reaction of 12 with 13b using a variety of acid catalysts (TMSOTf, Ti(Oi-Pr)4, 4 N 
HCl, AcOH, TFA, p-TsOH) in a range of solvents (THF, DCM, toluene, 
trifluoroethanol, hexafluoroisopropanol) all gave no or only trace amounts of product 
14 (not shown), except the combination of p-TsOH and toluene at reflux (entry 1). 
While, when using 2 equiv of urea the presence/absence of molecular sieves had no 
significant influence (entries 1,2), when 1 equiv of urea was used, the use of 
molecular sieves did lead to a higher yield (entries 3,4). Due to the possible lability of 
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Entry Lactol 13 
(equiv) 
Solvent PTSA 
(equiv) 
Drying 
agent 
Time 
(h) Work-up
 Et3N Column? Yield[a] (%)  
1 12 b (2) toluene 0.05 MS 18 [b] N 17 
2 12 b (2) toluene 0.05 - 5.5 [b] N 22 
3 12 b (1) toluene 0.05 - 5 [b] N 29 
4 12 b (1) toluene 0.05 MS 5.5 [b] N 38 
5 11 b (3.3) toluene 1.1 MS 20 [c] Y 65 
6 11 a (3) dioxane 1 MS 18 Aqueous Y 40 
7 11 a (5) dioxane 1 MS 44 Aqueous Y 59 
8 11 a (3) dioxane 1 Na2SO4 18 Aqueous Y 61 
9 11 a (3) dioxane 1 Na2SO4 36 Column Y 62 
10 11 a (5) dioxane 1 Na2SO4 72 Aqueous Y 64 
11 11 a (3) dioxane 1 Na2SO4 66 [c]
 
Y 65 
12 11 a (3) dioxane 1 Na2SO4 36 [d] N 79 
13 11 a (3) dioxane 1 - 36 [d]
 
N 76 
14 11 a (5) dioxane 1 Na2SO4 36 [d]
 
N 79 
15[e] 11 a (3) dioxane 1 Na2SO4 36 [d]
 
N 88 
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the TBDPS ether in acidic medium, further optimisation experiments were carried out 
with the 3,5-di-O-benzoyl-2-deoxy-2,2-difluororibose 11, obtained by reduction of the 
commercially available lactone. Indeed, reaction with 13b now gave a much 
improved 65% yield (entry 5), although a further increase in amount of urea was 
used. At this stage, it was decided to investigate the non-methylated urea 13a, which 
turned out to be unproblematic with regard to a sequential condensation process. 
The best solvent proved to be 1,4-dioxane (entry 6), giving a yield of 40%, with 39% 
recovered starting material, when using 1 equiv of p-TsOH. An increase in the 
relative amount of urea increased the yield to 59% (entry 7). As good conversion was 
seen by NMR analysis of crude material, losses during the workup due to difficult 
filtration of the molecular sieves were thought to be responsible for the reduced yield. 
However, a change of drying agent to Na2SO4 (entries 8–11), whilst facilitating the 
work-up, did not have a significant effect upon the yield, regardless of urea 
stoichiometry. Changing the workup to filtration over celite instead of silica gel did 
improve the yield (entry 12), though, surprisingly, the reaction without Na2SO4 
worked equally well (entry 13). Increasing the number of urea equivalents to 5 had 
no further beneficial effect (entry 14). Finally, reaction on 2.3 mmol scale under the 
best conditions led to an excellent 88% yield (entry 15) of the glycosyl ureas in a 
1:1.8 anomeric ratio. Unfortunately, assignment of the anomers could not be 
achieved. 
 
2.2 Formation of the cytosine nucleobase 
Next, acylation of the urea group with acyl chloride 16, synthesised by the method of 
Tietze,25 to give the nucleobase cyclisation precursor was investigated. Interestingly, 
this glycosyl urea acylation does not have a precedent for O-nucleosides, but has 
been demonstrated with carbanucleosides using pyridine with DMAP.26,27 However, 
reaction of 14a with 16 under those conditions (Table 2, entry 1), only afforded 30% 
of the desired product 17. Unexpectedly, significant anomerisation was observed, 
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which led to a decrease in anomeric ratio (1:2.4 to 1:1). This anomerisation may be 
due to urea deprotonation by pyridine (Scheme 4), facilitated by the electron 
withdrawing fluorines at the 2-position, to give the conjugate base 18. Anomerisation 
can then be envisaged by ring opening to 19 followed by non-selective ring closure. 
 
 
Scheme 4. Possible anomerisation mechanism 
 
Thus, the basic pyridine solvent was replaced by DCM, but even with 1 equiv of 
DMAP, none of the desired product was observed after 3.5 d (entry 2). Pleasingly, 
refluxing in acetonitrile with 2 equiv of 16 (entry 3) did yield the product in 45% yield, 
with a further improvement to 71% seen when the amount of 16 was increased to 
4 equiv (entry 4). These conditions also resulted in less anomerisation (1:2.4 to 
1:1.5). The same conditions with 1,4-dioxane as solvent gave a slightly lower yield, 
but more anomerisation was observed (entry 5). The least anomerisation was seen 
when ZnCl2 was employed, with a 1:1.9 anomeric ratio seen in the isolated product 
(entry 6), but a lower yield was obtained.  
 
Table 2. Optimisation of the urea acylation reaction. 
 
Entry Equiv 16 Reagents Solvent 
Temp 
(°C) Time Yield
[a]
 
Anomeric 
Ratio[b] 
1 1.5 
0.25 equiv 
DMAP 
Pyridine Reflux 40 h 30% 1:1 
2 1 1 equiv DMAP DCM RT 3.5 d 0% - 
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3 2 None MeCN Reflux 18 h 45% 1:1.5 
4 4 None MeCN Reflux 18 h 71% 1:1.5 
5 4 None Dioxane Reflux 18 h 61% 1:1.15 
6 3 0.25 equiv ZnCl2 CHCl3 Reflux 24 h 45% 1:1.9 
[a]
 isolated yield. [b] Determined by NMR analysis on the crude reaction mixture. 
 
 
Scheme 5. Conversion to gemcitabine 1 via the corresponding uridine 20. 
 
With the acyl carbamate 17 in hand, cyclisation to the protected difluorouridine 20 
was studied (Scheme 5) using methodology originally developed by Shaw.28 Among 
the various acidic protocols screened, HCl/AcOH emerged as the most efficient, 
leading to quantitative conversion to 20 in a 1:1.2 α/β mixture. Next, conversion of 
uridine to cytidine was effected using described methodology29,30 via the triazole 
intermediate 21 by treatment with 2-chlorophenyl phosphorodichloridate and 1,2,4-
triazole in pyridine, followed by reaction with ammonia. The ammonia treatment also 
caused concomitant benzoate deprotection, which then furnished gemcitabine 1 as a 
1:1.3 mixture of α:β anomers. 
 
3. Conclusion 
The linear synthesis of gemcitabine was achieved in 5 steps from a 2-deoxy-2,2-
difluororibose substrate with moderate anomeric selectivity. The demonstration of a 
high-yielding direct glycosyl urea formation through reaction of a reducing 2-deoxy-
2,2-difluorinated sugar derivative with urea will be of interest for other applications.  
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4. Experimental section 
4.1 Synthesis of the urea derivative 14a. Lactol 11 (870 mg, 2.30 mmol), urea (3 
equiv, 6.90 mmol, 414 mg), PTSA (1 equiv, 2.30 mmol, 437 mg) and Na2SO4 (2 
equiv, 4.60 mmol, 653 mg) were stirred in 1,4-dioxane (6.5 mL) at reflux for 36 h. The 
reaction mixture was cooled to RT, diluted with DCM and filtered through celite. The 
solvents were reduced in vacuo to yield a crude residue, which was purified by 
column chromatography on silica gel (10:90→40:60 acetone/petrol) to yield the 
desired glycosylurea 14a as a white foam, as a 1:1.8 anomeric mixture (853 mg, 
88%). IR (film) 3366 (br), 2925 (w), 1723 (m), 1678 (m), 1266 (s) cm–1. LRMS (ESI+) 
m/z 443.2 (M+Na)+ (100). HRMS (ESI+) for C20H18F2N2O6 (M+Na)+ calcd 443.1025, 
found 443.1018. 1H NMR (400 MHz, CDCl3) δ 8.04 (4 H, m, 4×CHAr), 7.61–7.33 (6 H, 
m, 6×CHAr), 6.69 (2/3 H, d, J = 10.0 Hz, NHMajor), 6.54 (1/3 H, d, J = 8.8 Hz, NHMinor), 
5.94 (1/3 H, q, J = 8.2 Hz, CHNHMinor), 5.78 (2/3 H, ddd, J = 14.4, 10.1, 5.4 Hz, 
CHNHMajor), 5.67 (1/3 H, ddd, J = 11.5, 8.1, 6.6 Hz, CHOBzMinor), 5.46 (2/3 H, m, 
CHOBzMajor), 5.34 (2/3 H, br.s, NH2Minor), 5.32 (4/3 H, br.s, NH2Major), 4.65–4.51 (7/3 H, m, 
CHCH2Minor, CH2), 4.36 (2/3 H, q, J = 4.3 Hz, CHCH2Major) ppm. 13C NMR + DEPT (100 
MHz, CDCl3) δ 166.3 (C=O), 165.0 (C=OMajor), 164.9 (C=OMinor), 157.8 (C=OMinor), 
157.7 (C=OMajor), 134.0 (CHAr), 133.9 (CHAr), 133.3 (CHAr), 130.0 (CHAr), 129.7 (CHAr), 
129.2 (CAr), 128.6 (CHAr), 128.5 (CHAr), 128.43 (CHAr), 128.38 (CHAr), 128.1 (CAr), 
121.4 (dd, J = 262.4, 257.6 Hz, CF2Minor), 120.4 (dd, J = 266.3, 253.7 Hz, CF2Major), 
81.9 (dd, J = 37.9, 19.4 Hz, CHNMinor), 81.2 (dd, J = 34.0, 20.4 Hz, CHNMajor), 77.2 (d, 
J = 5.8 Hz, CHCH2Minor), 76.0 (CHCH2Major), 72.3 (dd, J = 31.1, 17.5 Hz, CHOBzMinor), 
72.0 (dd, J = 36.0, 16.5 Hz, CHOBzMajor), 63.4 (CH2Minor), 63.3 (CH2Major) ppm (some 
CHAr overlap). 
Major Anomer: 19F NMR (282 MHz, CDCl3) δ –117.9 (1 F, dt, J = 246.6, 14.7 Hz, 
CFF), –122.9 (1 F, dd, J = 247.4, 5.2 Hz, CFF) ppm. 
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Minor Anomer: 19F NMR (282 MHz, CDCl3) δ –113.2 (1 F, d, J = 243.1 Hz, CFF), –
125.1 (1 F, dt, J = 244.0, 7.8 Hz, CFF) ppm. 
 
4.2 Synthesis of the N,N-dimethyl urea derivative 14b. To lactol 11 (35 mg, 0.09 
mmol) in toluene (1 mL) was added 3 Å molecular sieves (53 mg), N,N-dimethylurea 
(3 equiv, 0.30 mmol, 27 mg) and PTSA (1 equiv, 0.09 mmol, 19 mg). The reaction 
mixture was stirred at reflux for 20 h then cooled to RT and diluted with DCM before 
filtration through a plug of silica (pre-treated with Et3N), NaHCO3 and NaSO4. The 
solvents were reduced in vacuo to yield a crude residue which was purified by 
column chromatography on silica gel (15:85→25:75 acetone/hexane + 0.5% Et3N) to 
yield the desired glycosylurea 14b as an oil, as a 1:2.7 anomeric mixture (27 mg, 
65%). IR (film) 3307 (br), 2923 (w), 2853 (w), 1724 (s), 1659 (m), 1522 (m), 1266 (s), 
1095 (s) cm–1. LRMS (ESI+) m/z 919.5 (2M+Na)+ (100), 471.1 (M+Na)+ (71).  HRMS 
(ESI+) for C22H22F2N2O6 (M+Na)+ calcd 471.1338, found 471.1342. 1H NMR (400 
MHz, CDCl3) δ 8.09–8.03 (4 H, m, 4×CHAr), 7.65–7.39 (6 H, m, 6×CHAr), 6.12 (0.25 H, 
q, J = 8.2 Hz, CHNMinor), 5.89 (0.75 H, ddd, J = 14.9, 9.9, 5.2 Hz, CHNMajor), 5.72 
(0.25 H, ddd, J = 10.1, 8.3, 5.8 Hz, CHOBzMinor), 5.51 (0.75 H, dd, J = 15.6, 5.0 Hz, 
CHOBzMajor), 5.41 (0.25 H, d, J = 9.5 Hz, NHMinor), 5.28 (0.75 H, d, J = 9.8 Hz, NHMajor), 
4.67–4.56 (2.25 H, m, CH2OBz, CHCH2Minor), 4.40 (0.75 H, q, J = 4.4 Hz, CHCH2Major), 
2.98 (6 H, br. s, N(CH3)2) ppm. 13C NMR + DEPT (100 MHz, CDCl3) δ 166.0 (PhC=O), 
164.9 (PhC=O), 156.0 (NHC=O), 134.02 (CHAr), 133.98 (CHAr), 133.3 (CHAr), 130.0 
(CHAr), 129.9 (CHAr), 129.8 (CHAr), 129.4 (CHAr), 129.3 (CHAr), 128.6 (CHAr), 128.4 
(CHAr), 128.3 (CHAr), 128.2 (2×CAr), 82.1 (dd, J = 36.9, 18.5 Hz, CHNMinor), 81.6 (dd, 
J = 34.0, 19.4 Hz, CHNMajor), 77.1 (CHCH2Minor), 76.2 (t, J = 2.9 Hz, CHCH2Major), 72.6 
(dd, J = 31.1, 17.5 Hz, CHOBzMinor), 72.0 (dd, J = 36.0, 17.5 Hz, CHOBzMajor), 63.8 
(CH2Minor), 63.3 (CH2Major), 36.3 (N(CH3)2Major), 36.2 (N(CH3)2Minor) ppm (some CHAr 
overlap, CF2 not visible). 
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Major anomer: 19F NMR (282 MHz, CDCl3) δ –118.4 (1 F, dt, J = 247.1, 15.0 Hz, 
CFF), –123.3 (1 F, dd, J = 247.1, 5.4 Hz, CFF) ppm. 
Minor anomer: 19F NMR (282 MHz, CDCl3) δ –114.9 (1 F, dt, J = 243.9, 9.7 Hz, CFF), 
–126.4 (1 F, dt, J = 242.8, 8.6 Hz, CFF) ppm. 
 
4.3 Synthesis of the N,N-dimethyl urea derivative 15b. To lactol 12 (102 mg, 0.20 
mmol) in toluene (0.8 mL) was added N,N-dimethylurea (1 equiv, 0.16 mmol, 18 mg), 
a catalytic amount of PTSA and molecular sieves (90 mg). The reaction mixture was 
stirred at reflux for 5.5 h, cooled to RT and the solvents removed in vacuo to yield a 
crude residue. This residue was first purified by column chromatography on silica gel 
(10:90 acetone/hexane) followed by HPLC (10:90 acetone/hexane) to yield 15b as a 
colourless oil as a 1:2.9 anomeric mixture (44 mg, 38%). IR (film) 3070 (w), 2930 (m), 
2857 (m), 1472 (m), 1456 (m) cm–1. 
Major anomer: 1H NMR (400 MHz, acetone-d6) δ 7.76–7.67 (4 H, m, 4×ArH), 7.49–
7.31 (11 H, m, 11×ArH), 4.87 (1 H, d, J = 11.8 Hz, OCHHPh), 4.66 (1 H, d, J = 
11.6 Hz, OCHHPh), 4.63 (1 H, m, CHN), 4.23 (1 H, ddd, J = 12.3, 11.2, 8.3 Hz, 
CHOBn), 3.97 (1 H, m, CHCH2OSi), 3.84 (1 H, dd, J = 11.6, 3.5 Hz, CHHOSi), 3.75 
(1 H, m, CHHOSi), 2.47 (6 H, s, N(CH3)2), 1.01 (9 H, s, C(CH3)3) ppm (NH not 
visible). 13C NMR + DEPT (100 MHz, acetone-d6) δ 182.2 (C=O), 138.6 (CAr), 136.5 
(2×CHAr), 134.1 (2×CAr), 130.84 (2×CHAr), 130.76 (2×CHAr), 129.3 (2×CHAr), 128.8 
(5×CHAr), 128.7 (2×CHAr), 125.1 (dd, J = 259.5, 255.1 Hz, CF2), 96.6 (dd, J = 31.8, 
24.3 Hz, CHN), 81.7 (CHCH2), 77.7 (m, CHOBn), 73.3 (CH2), 63.3 (CH2), 41.0 
(N(CH3)2), 27.3 (C(CH3)3), 19.9 (C(CH3)3) ppm. 19F NMR (376 MHz, acetone-d6) δ –
112.3 (1 F, ddd, J = 240.3, 14.3, 11.0 Hz, CFF), –113.0 (1 F, dt, J = 240.3, 11.8 Hz, 
CFF) ppm. 
Minor anomer: 1H NMR (400 MHz, acetone-d6) δ 7.76–7.67 (4 H, m , 4×ArH), 7.49–
7.31 (11 H, m, 11×ArH), 4.86 (1 H, d, J = 11.9 Hz, OCHHPh), 4.74 (1 H, t, J = 
11.1 Hz, CHN), 4.65 (1 H, d, J = 11.7 Hz, OCHHPh), 4.39 (1 H, ddd, J = 12.2, 9.2, 
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7.1 Hz, CHOBn), 4.09 (1 H, dtd, J = 6.9, 3.4, 1.3 Hz, CHCH2OSi), 3.86 (1 H, m, 
CHHOSi), 3.76 (1 H, m, CHHOSi) 2.44 (6 H, s, N(CH3)2), 1.02 (9 H, s, C(CH3)3) ppm 
(NH not observed). 13C NMR + DEPT (100 MHz, acetone-d6) δ 182.2 (C=O), 138.6 
(CAr), 136.5 (2×CHAr), 134.0 (2×CAr), 130.9 (2×CHAr), 130.8 (2×CHAr), 129.4 (2×CHAr), 
128.8 (5×CHAr), 128.7 (2×CHAr), 96.1 (dd, J = 36.4, 18.0 Hz, CHN), 81.6 (CHCH2), 
77.9 (m, CHOBn), 73.4 (CH2), 64.4 (CH2), 41.4 (N(CH3)2), 27.3 (C(CH3)3), 19.9 
(C(CH3)3) ppm (CF2 not observed). 19F NMR (376 MHz, acetone-d6) δ –105.4 (1 F, dt, 
J = 240.8, 11.8 Hz, CFF), –126.4 (1 F, dt, J = 240.3, 11.0 Hz, CFF) ppm. 
 
4.4 Synthesis of 17. To glycosylurea 14a (93 mg, 0.22 mmol) stirring at reflux in 
MeCN (0.6 mL) was added dropwise a solution of acyl chloride 16 (4 equiv, 0.88 
mmol, 119 mg) in MeCN (0.4 mL). The reaction mixture was stirred at reflux for 18 h, 
then quenched with water (0.1 mL). The solvents were reduced in vacuo to yield a 
crude residue which was taken up in DCM (15 mL), washed with water (5 mL), then 
brine and dried over anhydrous MgSO4. The solvents were reduced in vacuo to yield 
a crude residue which was purified by flash chromatography on silica gel 
(10:90→40:60 acetone/petrol) to yield the desired product 17 as a colourless oil as a 
1:1.5 mixture of anomers (82 mg, 71%). IR (film) 3246 (br), 2981 (w), 1717 (s), 1680 
(s), 1603 (m), 1537 (s), 1492 (w), 1452 (m), 1378 (w), 1316 (m), 1247 (s), 1176 (m), 
1093 (s) cm–1. LRMS (ESI+) m/z 1059.8 (2M+Na)+ (50), 541.3 (M+Na)+ (100).  HRMS 
(ESI+) for C25H24F2N2O8 (M+Na)+ Calcd: 541.1393; Found: 541.1411. 1H NMR (400 
MHz, CDCl3) δ 10.01 (0.5 H, d, J = 9.2 Hz, 0.5×CHNH), 9.79 (0.5 H, d, J = 9.5 Hz, 
0.5×CHNH), 9.65 (0.5 H, s, 0.5×O=CNHC=O), 9.28 (0.5 H, s, 0.5×O=CNHC=O), 
8.22–8.20 (1 H, m, CHAr), 8.08–8.02 (3 H, m, 3×CHAr), 7.69 (1 H, d, J = 11.9 Hz, 
HC=CHOEt), 7.65–7.40 (6 H, m, 6×CHAr), 6.08 (0.5 H, t, J = 9.3 Hz, 0.5×CHN), 5.90 
(0.5 H, ddd, J = 12.9, 9.5, 6.0 Hz, 0.5×CHN), 5.70–5.67 (0.5 H, m, 0.5×CHOBn), 5.57 
(0.5 H, ddd, J = 14.7, 5.1, 1.0 Hz, 0.5×CHOBn), 5.37 (0.5 H, d, J = 12.1 Hz, 
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0.5×CHOEt), 5.34 (0.5 H, d, J = 12.0 Hz, 0.5×CHOEt), 4.69–4.58 (2.5 H, m, CHCH2, 
0.5×CHCH2), 4.43 (0.5 H, q, J = 4.5 Hz, 0.5×CHCH2), 3.98 (2 H, q, J = 7.1 Hz, 
CH2CH3), 1.34 (1.5 H, t, J = 7.0 Hz, 0.5×CH3), 1.33 (1.5 H, t, J = 7.1 Hz, 0.5×CH3) 
ppm. 13C NMR + DEPT (100 MHz, CDCl3) δ 168.3 (0.5×C=OCH=CH), 168.1 
(0.5×C=OCH=CH), 166.07 (0.5×PhCOCH2), 166.05 (0.5×PhCOCH2), 164.9 
(0.5×PhCOCH), 164.7 (0.5×PhCOCH), 164.0 (0.5×CH=CHOEt), 163.6 
(0.5×CH=CHOEt), 155.1 (0.5×NC=ON), 154.9 (0.5×NC=ON), 134.0 (CHAr), 133.3 
(CHAr), 133.2 (CHAr), 130.4 (CHAr), 130.0 (CHAr), 129.8 (CHAr), 128.6 (CHAr), 128.5 
(CHAr), 128.4 (CHAr), 129.33 (0.5×CAr), 129.30 (0.5×CAr), 128.2 (0.5×CAr), 128.0 
(0.5×CAr), 97.5 (HC=CHOEt), 81.2 (dd, J = 39.5, 22.0 Hz, 0.5×CHN), 80.5 (dd, J = 
36.6, 22.0 Hz, 0.5×CHN), 79.3 (0.5×CHCH2), 76.7 (0.5×CHCH2), 72.2 (dd, J = 33.7, 
17.6 Hz, 0.5×CHOBz), 72.0 (dd, J = 35.1, 17.6 Hz, 0.5×CHOBz), 68.0 (0.5×CH2CH3), 
67.7 (0.5×CH2CH3), 63.3 (0.5×CHCH2), 63.2 (0.5×CHCH2), 14.43 (0.5×CH3), 14.36 
(0.5×CH3) ppm (some CHAr overlap, CF2 not visible). 19F NMR (282 MHz, CDCl3) δ 
Anomer 1: –109.5 (1 F, ddd, J = 251.4, 16.1, 6.4 Hz, CFF), –125.4 (1 F, d, J = 252.5 
Hz, CFF) ppm; Anomer 2: –123.6 (1 F, dd, J = 241.8, 9.7 Hz, CFF), –125.5 (1 F, ddd, 
J = 241.8, 10.7, 6.4 Hz, CFF) ppm. (Data assigned from an earlier experiment which 
gave a 1:1 mixture of anomers). 
 
4.5 Synthesis of the uridine 20. Acyl carbamate 17 (136 mg, 0.26 mmol) was 
stirred in 1:10 HCl/AcOH (2.75 mL) at RT in a stoppered flask for 24 h. The solvents 
were reduced in vacuo to yield the desired protected difluorouracil 20 as a yellow oil 
as a 1:1.2 α/β mixture of anomers (125 mg, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ 8.91 (1 H, br. s, NH), 8.11–8.02 (4 H, m, CHAr), 7.69–
7.39 (7 H, m, 6×CHAr, NCH=CH), 6.55 (0.45 H, t, J = 7.5 Hz, CHNα), 6.40 (0.55 H, 
dd, J = 11.8, 6.4 Hz, CHNβ), 5.82 (0.45 H, d, J = 8.1 Hz, NCH=CHα), 5.79 (0.45 H, m, 
CHOBzα), 5.68 (0.55 H, d, J = 8.3 Hz, NCH=CHβ), 5.65 (0.55 H, m, CHOBzβ), 4.89–
4.81 (1 H, m, CHCHH), 4.73–4.59 (2 H, m, CHO, CHCHH) ppm. 19F NMR (282 MHz, 
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CDCl3) δ –109.2 (0.45 F, d, J = 249.3 Hz, CFF), –115.5 (0.55 F, dt, J = 247.4, 12.9 
Hz, CFF), –120.3 (0.5 F, d, J = 246.6 Hz, CFF), –122.0 (0.5 F, d, J = 250.9 Hz, CFF) 
ppm. 
 
4.6 Synthesis of gemcitabine 1. To crude protected difluorouridine 20 (378 mg, 
0.75 mmol) in pyridine (9 mL) was added 1,2,4-triazole (3 equiv, 2.26 mmol, 156 mg) 
and 2-chlorophenyl phosphorodichloridate (6 equiv, 4.51 mmol, 0.74 mL). The 
reaction mixture was stirred at RT for 5 d. The solvents were reduced in vacuo to 
yield a crude residue which was taken up in DCM and washed with sat. NaHCO3 
(aq), then brine and dried over anhydrous Na2SO4. The solvents were reduced in 
vacuo to yield a crude oil which was passed through a short silica column (10:90 
acetone/petrol) to yield the impure triazole 21 (94 mg, ~24%). This triazole (76.5 mg, 
0.17 mol) was stirred in 7 N NH3 in MeOH (5 mL) at RT for 36 h. The solvents were 
reduced in vacuo and the resultant residue evaporated onto silica gel for purification 
by column chromatography (10:90–20:80 MeOH/DCM) to yield the desired 
difluorocytidine 1 as a 1:1.3 α/β mixture of anomers (18.7 mg, 49%). 1H NMR (400 
MHz, DMSO-d6) δ 7.69 (0.6 H, d, J = 7.6 Hz, NCH=CHβ), 7.52 (0.4 H, dd, J = 7.5, 1.6 
Hz, NCH=CHα), 7.37–7.30 (2 H, m, NH2), 6.30–6.26 (0.8 H, m, CHNα, CHOHα), 6.22 
(0.6 H, d, J = 6.6 Hz, CHOHβ), 6.13 (0.6 H, t, J = 8.3 Hz, CHNβ), 5.79 (0.4 H, d, J = 
7.5 Hz, NCH=CHα), 5.78 (0.6 H, d, J = 7.6 Hz, NCH=CHβ), 5.19 (0.6 H, t, J = 5.4 Hz, 
CH2OHβ), 5.07 (0.4 H, t, J = 5.7 Hz, CH2OHα), 4.34 (0.4 H, m, CHOHα),  4.18–4.07 
(1.2 H, m, CHOHβ, CHCH2(β)), 3.81–3.74 (1 H, m, CHCH2α, CHCHHβ), 3.64–3.59 (1 
H, m, CHCHH), 3.53 (0.4 H, m, CHCHHα) ppm. 13C NMR + DEPT (100 MHz, DMSO-
d6) δ 165.7 (0.5×NCON), 165.6 (0.5×NCON), 154.8 (0.5×N=C), 154.7 (0.5×N=C), 
141.3 (0.5×NC=C), 140.8 (0.5×NC=C), 123.1 (t, J = 252.6 Hz, CF2), 94.6 
(0.5×NC=C), 94.4 (0.5×NC=C), 83.9–83.2 (m, CHN), 80.4 (CHCH2), 69.6 (dd, J = 
26.3, 17.6 Hz, 0.5×CHOH), 68.7 (t, J = 22.0 Hz, CHOH), 60.0 (0.5×CH2), 59.0 
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(0.5×CH2) ppm. 19F NMR (282 MHz, DMSO-d6) δ –114.3 (0.4 F, d, J = 232.8 Hz, 
CFFα), –115.5––117.3 (1.2 F, m, CF2(β)), –124.3 (0.4 F, d, J = 234.5 Hz, CFFα) ppm. 
Data consistent with the literature.12 
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* A linear synthesis of gemcitabine has been achieved 
* The key step is a urea introduction to an unactivated 2,2-difluorinated furanose  
* Only moderate anomeric selectivity was obtained 
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General information: 
1H and 13C NMR spectra were recorded at room temperature on a Bruker DPX400 or 
AV300 spectrometer as indicated. Chemical shifts are quoted in ppm relative to 
residual solvent peaks as appropriate. 19F NMR spectra were recorded on a Bruker 
AV300 spectrometer or a Bruker DPX400 spectrometer and are referenced to C6F6 
and CFCl3 respectively. Assignments were assisted by COSY and HMQC 
experiments. LRMS were recorded on a Thermoquest Trace GCMS Quadrapole 
system. HRMS were recorded on a VG Analytical 70-250-SE, normal geometry, 
double focussing. Infrared spectra were recorded as neat films on a Thermo Matson 
Fourier Transform spectrometer. Melting points were recorded on a Gallencamp 
Melting Point Apparatus and are uncorrected. Column chromatography was 
performed on silica gel (60 Å, 35-70 microns). Preparative HPLC was carried out 
using a Biorad Biosil D 90-10, 250 × 22 mm column eluting at 20 mL min-1, 
connected to a Kontron 475 refractive index detector. Reactions were monitored by 
TLC (Merck). Reaction solvents were dried before use as follows: THF and Et2O 
were distilled from sodium/benzophenone ketyl; DCM, pyridine and Et3N were 
distilled from CaH2; toluene was distilled from Na; MeCN was dried over 3 Å 
molecular sieves. Reaction vessels were flame dried under vacuum and cooled 
under N2 prior to use and all experiments were carried out under a N2 atmosphere. 
All other reagents were purchased from commercial sources and used without 
further purification. 
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1) Urea 14a 
 1H, CDCl3, 400 MHz 
KJB-5977-14B 1H au3110njwkjb1.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0.652.391.840.640.370.620.340.290.586.144.00
 13C, CDCl3, 100 MHz  
KJB-5977-14B 13C au3110njwkjb1.esp
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19F, CDCl3, 282 MHz 
KJB-5977-14B 19F se0410kjb1.esp
-105 -110 -115 -120 -125 -130 -135 -140 -145 -150
Chemical Shift (ppm)  
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2) Urea 14b 
 1H, CDCl3, 400 MHz 
KJB-5458-97A 1H ju1009kjb2.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
6.000.752.250.750.250.750.250.750.256.004.00
13C, CDCl3, 100 MHz 
KJB-5458-97A 13C ju1009kjb2.esp
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 19F, CDCl3, 282 MHz 
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ju0909kjb1.011.esp
-70 -75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140 -145 -150 -155
Chemical Shift (ppm)
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3) Acyl carbamate 17 
 
 1H, CDCl3, 400 MHz 
KJB-5977-50B H4 1H nv0410kjb5.esp
10 9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
3.002.000.502.501.000.500.500.500.506.001.003.001.000.500.500.500.50
13C, CDCl3, 100 MHz 
KJB-5977-50B H4 13C nv0410kjb5.esp
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19F, CDCl3, 282 MHz 
nv0410kjb4.011.esp
-90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140
Chemical Shift (ppm)
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4) Uridine 20, including comparison with commercial sample 
 1H, CDCl3, 300 MHz 
KJB-7027-10 crude ja1811kjb4.esp
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
2.001.001.100.900.550.457.004.00
 
Commercial Sample, β anomer only, 
1
H NMR, CDCl3, 400 MHz  
Desktop.100.esp
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1.001.001.002.001.001.004.002.004.00
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19F, CDCl3, 282 MHz 
ja1811kjb4.011.esp
-75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140 -145
Chemical Shift (ppm)  
Commercial Sample, β anomer only, 
1
F NMR, CDCl3, 376 MHz  
Desktop.041.esp
-75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140 -145
Chemical Shift (ppm)
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5) Gemcitabine 1, including comparison with commercial sample 
 1H, DMSO, 400 MHz
Gemcitabine 1H DMSO fe0511kjb5.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0.401.001.001.200.400.400.601.000.601.402.000.400.60
 
 
Commercial Sample, β anomer only, 
1
H NMR, DMSO, 400 MHz  
Desktop.070.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1.002.001.001.001.001.001.002.001.00
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19F, CDCl3, 282 MHz 
 
 
Commercial Sample, β anomer only, 
1
F NMR, DMSO, 376 MHz  
 
Desktop.031.esp
-40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190
Chemical Shift (ppm)
 
